TEM-158 was found to include the substitutions previously observed for TEM-12 and TEM-35. This enzyme presented hydrolytic activity against ceftazidime and a high level of resistance against clavulanate, which can alter its detection. Its discovery highlights the need for accurate detection methods.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2151416 | PMC |
| http://dx.doi.org/10.1128/AAC.00614-07 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
In vivo selection of a complex mutant TEM (CMT) from an inhibitor-resistant TEM (IRT) during ceftazidime therapy.
J Antimicrob Chemother
December 2013
APHP, Hôpital Lariboisière, Service de Bactériologie, Paris, France.
Objectives: A relapse from Escherichia coli bloodstream infection was observed in a patient with acute leukaemia treated with ceftazidime for 7 days for febrile neutropenia. Whereas the original E. coli isolate was resistant to β-lactam/β-lactamase inhibitor combinations (EC1), the relapse E.
View Article and Find Full Text PDFTEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.
Antimicrob Agents Chemother
November 2007
CHU Clermont-Ferrand, Centre de Biologie, Laboratoire de bactériologiecinique, Faculté de Médecine, 28 place H. Dunant, 63001 Clermont-Ferrand, France.
TEM-158 was found to include the substitutions previously observed for TEM-12 and TEM-35. This enzyme presented hydrolytic activity against ceftazidime and a high level of resistance against clavulanate, which can alter its detection. Its discovery highlights the need for accurate detection methods.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!